FIG. 1A



SDSA25 Dexamethasone Release at 37°C (0.1% Triton X-100)
% Dexamethasone Released (n=6)
150
100
50
0
0 28 56 84 112 140 168 196 224 252 280 308
Time (Days)
ENV-1R-0119-7-1 RG502S/RG502H (50/50)
ENV-1R-0119-7-2 RG502S
ENV-1R-0119-7-3 RG502H
ENV-1R-0119-7-4 RG503S/RG502H (50/50)
ENV-1R-0119-7-5 R203S/RG502S(50/50)
ENV-1R-0119-7-6 R203S/RG502H(50/50)
ENV-1R-0119-7-7 R203S/RG502S(70/30)

FIG. 1B



SDSA25 Dexamethasone Release at 37°C (0.1% Triton X-100)
% Dexamethasone Released (n=6)
150
100
50
0
0 28 56 84 112 140 168 196 224 252 280 308
Time (Days)
ENV-1R-0119-7-12 RG755S
ENV-1R-0119-7-14 RG752H/PEG400(95/5)
ENV-1R-0119-7-15 RG752S/RG755S(80/20)
ENV-1R-0119-7-16 RG752H/RG755S (80/20)

FIG. 1C



SDSA25 Dexamethasone Release at 37°C (0.1% Triton X-100)
% Dexamethasone Released (n=6)
150
100
50
0
0 28 56 84 112 140 168 196 224 252 280 308
Time (Days)
ENV-1R-0119-7-8 DLG 3A
ENV-1R-0119-7-9 DLG 4A
ENV-1R-0119-17-1 R203S/DLG1A (70/30)
ENV-1R-0119-17-2 R203S/DLG1A (85/15)
ENV-1R-0119-17-3 R203S/DLG1A (95/5)

FIG. 2



SDSA34 Release at 37C at sink conditions (0.1% Triton X-100)
% Dexamethasone Released (n=6)
150
125
100
75
50
25
0
0 28 56 84 112 140 168 196 224 252 280 308 336
Time (Days)
ENV-1R-119-39-1, R203S/R207S 70/30
ENV-1R-119-39-2, R203S/R205S 70/30
ENV-1R-119-39-3, R203S/R208S 70/30
ENV-1R-119-39-4, R203S/R207S 50/50
ENV-1R-119-39-5, R203S/R208S 50/50

FIG. 3



SDSA 39 Release at 37C at sink conditions (0.1% Triton X-100)
% Dexamethasone Released (n=5)
250
200
150
100
50
0
0
28
56
84
112
140
168
Time (Days)
ENV-1R-119-36-1, R205S/ DLG2A (50/50)
ENV-1R-119-36-2, R208S/ DLG2A (50/50)
ENV-1R-119-36-3, R205S/ R203S (70/30)
ENV-1R-119-36-4, R205S/ DLG1A (50/50)
ENV-1R-119-36-5, R205S/ DLG1A (70/30)

FIG. 4A



SDSA 41 Release at 37C at sink conditions (0.1% Triton X-100)
% Dexamethasone Released (n=6)
120
100
80
60
40
20
0
0
28
56
84
112
140
168
196
224
Time (Days)
ENV-1R-119-42-1, RG504H/ R203S (50/50)
ENV-1R-119-42-2, RG504H/ R203S (70/30)
ENV-1R-119-42-3, RG504H/ R203S (85/15)

FIG. 4B



SDSA 41 Release at 37C at sink conditions (0.1% Triton X-100)
% Dexamethasone Released (n=6)
300
250
200
150
100
50
0
0
28
56
84
112
140
168
196
224
Time (Days)
ENV-1R-119-42-4, RG503H/ R203S (50/50)
ENV-1R-119-42-5, RG503H/ R203S (70/30)
ENV-1R-119-42-6, RG503H/ R203S (85/15)
ENV-1R-119-42-7, RG503H/ R203S (30/70)

FIG. 4C



SDSA 41 Release at 37C at sink conditions (0.1% Triton X-100)
% Dexamethasone Released (n=6)
150
125
100
75
50
25
0
0
28
56
84
112
140
168
196
224
Time (Days)
ENV-1R-119-42-8, RG653H/ R203S (50/50)
ENV-1R-119-42-9, RG653H/ R203S (70/30)
ENV-1R-119-42-10, RG653H/ R203S (85/15)

FIG. 4D



SDSA 41 Release at 37C at sink conditions (0.1% Triton X-100)
% Dexamethasone Released (n=6)
150
125
100
75
50
25
0
0
28
56
84
112
140
168
196
224
252
280
308
Time (Days)
ENV-1R-119-42-11, R203S/ R208S (85/15)
ENV-1R-119-42-12, R203S/ R207S (85/15)
ENV-1R-119-42-13, R203S/ R205S (85/15)
ENV-1R-119-42-14, R203S/ DLG2A (70/30)

FIG. 5



SDSA 53 Dexamethasone Release at 37C (0.1% Triton X-100)
% Dexamethasone Released (n=5)
400
350
300
250
200
150
100
50
0
0
28
56
84
112
140
168
196
224
252
Time (Days)
ENV-1R-0119-45-1 RG502
ENV-1R-0119-45-2 R203/RG502S (50/50)
ENV-1R-0119-45-3 R203/RG502S (70/30)
ENV-1R-0119-45-4 R203/RG502H (50/50)
ENV-1R-0119-45-5 R203/DLG1A (95/5)
ENV-1R-0119-45-6 R203/DLG1A (85/15)
ENV-1R-0119-45-7 RG752S/RG755S (70/30)
ENV-1R-0119-45-8 RG752S/RG755S (60/40)

FIG. 6A



SDSA 70 Dexamethasone Release at 37C (0.1% Triton X-100)
% Dexamethasone (n=5)
0
20
40
60
80
100
120
140
0
14
28
42
56
70
84
98
112
126
Time (Days)
ENV-1D-0209-1-22 503H/203S (90/10)
ENV-1D-0209-1-6 503H/203S (70/30)
ENV-1D-0209-1-5 503H/203S (85/15)

FIG. 6B



SDSA 70 Dexamethasone Release at 37C (0.1% Triton X-100)
% Dexamethasone (n=5)
0
20
40
60
80
100
120
140
0 14 28 42 56 70 84 98 112 126 140 154 168 182 196
Time (Days)
ENV-1D-0209-1-8 503S/203S (85/15)
ENV-1D-0209-1-7 503S/203S (70/30)

FIG. 6C



SDSA 70 Dexamethasone Release at 37C (0.1% Triton X-100)
% Dexamethasone (n=5)
0
20
40
60
80
100
120
140
0 14 28 42 56 70 84 98 112 126 140 154 168 182 196
Time (Days)
ENV-1D-0209-1-21 503H/205S (85/15)
ENV-1D-0209-1-20 503H/205S (90/10)
ENV-1D-0209-1-2 503H/205S (10/90)
ENV-1D-0209-1-1 503H/205S (30/70)

FIG. 6D



SDSA 70 Dexamethasone Release at 37C (0.1% Triton X-100)
% Dexamethasone (n=5)
0
20
40
60
80
100
120
140
0 14 28 42 56 70 84 98 112 126 140 154 168 182 196
Time (Days)
ENV-1D-0209-1-4 503S/205S (15/85)
ENV-1D-0209-1-3 503S/205S (30/70)

FIG. 6E



SDSA 70 Dexamethasone Release at 37C (0.1% Triton X-100)
% Dexamethasone (n=5)
0
20
40
60
80
100
120
140
0
28
56
84
112
140
168
196
224
Time (Days)
ENV-1D-0209-1-19 205/653H (70/30)
ENV-1D-0209-1-18 205/653H (85/15)
ENV-1D-0209-1-17 205/653H (95/5)

FIG. 6F



SDSA 70 Dexamethasone Release at 37C (0.1% Triton X-100)
% Dexamethasone (n=5)
0
20
40
60
80
100
120
140
0
14
28
42
56
70
84
98
112
126
Time (Days)
ENV-1D-0209-1-11 502S/208/203 (10/50/40)
ENV-1D-0209-1-9 502S/208/203 (10/23/67)
ENV-1D-0209-1-10 502S/208/203 (10/40/50)

FIG. 6G



SDSA 70 Dexamethasone Release at 37C (0.1% Triton X-100)
% Dexamethasone (n=5)
0
20
40
60
80
100
120
140
0
28
56
84
112
140
168
196
224
Time (Days)
ENV-1D-0209-1-12 502S/205/203 (10/60/30)
ENV-1D-0209-1-13 502S/205/203 (10/70/20)

FIG. 6H



SDSA 70 Dexamethasone Release at 37C (0.1% Triton X-100)
% Dexamethasone (n=5)
140
120
100
80
60
40
20
0
0
14
28
42
56
70
84
98
112
126
140
154
Time (Days)
ENV-1D-0209-1-14 502S/205 (20/80)

FIG. 6I



SDSA 70 Dexamethasone Release at 37C (0.1% Triton X-100)
% Dexamethasone (n=5)
0
20
40
60
80
100
120
140
0
14
28
42
56
70
84
98
112
126
140
Time (Days)
ENV-1D-0209-1-16 205/2A (90/10)
ENV-1D-0209-1-15 205/1A (95/5)

FIG. 7A



SDSA 75/76
Solid lines: 1XPBS
Dotted lines: 1X PBS + 0.1% Triton X-100
% Dexamethasone (n=5)
120
110
100
90
80
70
60
50
40
30
20
10
0
0
28
56
84
112
140
168
196
Time (Days)
209-10-1, R203/RG752S 85/15
209-10-2, R203/RG752S 70/30
209-10-3, R203/RG752S 50/50
209-10-1, R203/RG752S 85/15
209-10-2, R203/RG752S 70/30
209-10-3, R203/RG752S 50/50

FIG. 7B



SDSA 75/76
Solid lines: 1XPBS
Dotted lines: 1X PBS +0.1% Triton X-100
% Dexamethasone (n=5)
110
100
90
80
70
60
50
40
30
20
10
0
0
28
56
84
112
140
168
196
Time (Days)
209-10-4, R203/RG504H 15/85
209-10-5, R203/RG504H 30/70
209-10-4, R203/RG504H 15/85
209-10-5, R203/RG504H 30/70

FIG. 7C



SDSA 75/76
Solid lines: 1XPBS
Dotted lines: 1X PBS + 0.1% Triton X-100
% Dexamethasone (n=5)
0
10
20
30
40
50
60
70
80
90
100
110
0
28
56
84
112
140
168
196
Time (Days)
209-10-6, R203/RG755S 85/15
209-10-7, R203/RG755S 70/30
209-10-8, R203/RG755S 50/50

FIG. 7D



SDSA 75/76
Solid lines: 1XPBS
Dotted lines: 1X PBS + 0.1% Triton X-100
% Dexamethasone (n=5)
110
100
90
80
70
60
50
40
30
20
10
0
0
28
56
84
112
140
168
196
Time (Days)
209-10-9, RG755S/RG752S 20/80
209-10-10, RG755S/RG752S 35/65
209-10-9, RG755S/RG752S 20/80
209-10-10, RG755S/RG752S 35/65

FIG. 7E



SDSA 75/76
Solid lines: 1XPBS
Dotted lines: 1X PBS + 0.1% Triton X-100
% Dexamethasone (n=5)
110
100
90
80
70
60
50
40
30
20
10
0
0
28
56
84
112
140
168
196
Time (Days)
209-10-11, R203/ DLG 1A 95/5
209-10-12, R203/ DLG 1A 80/20
209-10-13, R205/ DLG 1A 95/5
209-10-14, R205/ DLG 2A 90/10

FIG. 7F



SDSA 75/76
Solid lines: 1XPBS
Dotted lines: 1X PBS + 0.1% Triton X-100
% Dexamethasone (n=5)
120
110
100
90
80
70
60
50
40
30
20
10
0
0
28
56
84
112
140
168
196
Time (Days)
209-10-15, R205/RG653H 85/15
209-10-16, R205/RG653H 70/30
209-10-17, R205/RG653H 50/50

FIG. 7G



SDSA 75/76
Solid lines: 1XPBS
Dotted lines: 1X PBS + 0.1% Triton X-100
% Dexamethasone (n=5)
100
90
80
70
60
50
40
30
20
10
0
0
28
56
84
112
140
168
196
Time (Days)
209-10-18, R203/RG653H 85/15
209-10-20, R203/RG653H 50/50
209-10-19, R203/RG653H 60/40

FIG. 7H



SDSA 75/76
Solid lines: 1XPBS
Dotted lines: 1X PBS + 0.1% Triton X-100
% Dexamethasone (n=5)
100
90
80
70
60
50
40
30
20
10
0
0
28
56
84
112
140
168
196
Time (Days)
209-10-21, R203/RG502S 50/50
209-10-21, R203/RG502S 50/50

FIG. 8



SDSA 97 Dexamethasone Release at 37C in 1X PBS
% Dexamethasone (n=5)
100
90
80
70
60
50
40
30
20
10
0
0
14
28
42
56
70
84
98
112
Time (Days)
ENV-1D-0209-12-1, 203S/752S 85/15
ENV-1D-0209-12-2, 203S/752S 85/15
ENV-1D-0209-12-3, 203S/752S 85/15

FIG. 9



Dexamethasone Release at 37C in 1X PBS
% Dexamethasone (n=5)
100
90
80
70
60
50
40
30
20
10
0
0 14 28 42 56 70 84 98 112 126 140 154 168 182 196
Time (Days)
RES-DME-0005-27-2, 504H/203S 70/30
RES-DME-0015-6-19, 203/653 (60/40)

FIG. 10



Fluocinolone Release at 37C in 0.1% Trition X-100 at sink conditions
% Fluocinolone released (n=6)
0
20
40
60
80
100
120
140
0
28
56
84
112
140
168
196
224
252
280
Time (Days)
ENV-1R-0119-33-1 R208/2A (85/15)
ENV-1R-0119-33-2 R208/2A (70/30)
ENV-1R-0119-33-3 R203/2A (50/50)
ENV-1R-0119-33-4 R203/2A (70/30)
ENV-1R-0119-33-5 R203/2A (85/15)
ENV-1R-0119-33-6 R203
ENV-1R-0119-33-7 R203/1A 95/15
ENV-1R-0119-33-8 RG502S
ENV-1R-0119-33-9 RG502S/RG502H (85/15)
ENV-1R-0119-33-10 RG502S/RG502H (95/5)

FIG. 11



SDSA35 Release at 37C at sink conditions (0.1% Triton X-100)
% Fluocinolone Released (n=6)
120
100
80
60
40
20
0
0
28
56
84
112
140
168
196
224
252
280
Time (Days)
ENV-1R-119-38-1, R208S/DLG2A 70/30
ENV-1R-119-38-5, R208S/DLG1A 85/15
ENV-1R-119-38-6, R207S/R203S 70/30
ENV-1R-119-38-7, R207S/DLG2A 70/30
ENV-1R-119-38-8, R205S/R203S 70/30
ENV-1R-119-38-9, R203S/R205S 70/30
ENV-1R-119-38-10, R203S/R207S 70/30
ENV-1R-119-38-11, R203S/R208S 70/30
ENV-1R-119-38-12, R203S/R208S 50/50

FIG. 12



SDSA 46 Release at 37C at sink conditions (0.1% Triton X-100)
% Fluocinolne Released (n=5)
120
100
80
60
40
20
0
0
28
56
84
112
140
168
196
Time (Days)
ENV-1R-0119-44-1 RG504H/R203S (50/50)
ENV-1R-0119-44-2 RG504H/R203S (70/30)
ENV-1R-0119-44-3 RG504H/R203S (85/15)
ENV-1R-0119-44-4 RG503H/R203S (50/50)
ENV-1R-0119-44-5 RG503H/R203S (70/30)
ENV-1R-0119-44-6 RG503H/R203S (85/15)
ENV-1R-0119-44-7 RG503H/R203S (30/70)
ENV-1R-0119-44-9 RG653H/R203S (70/30)
ENV-1R-0119-44-10 RG653H/R203S (85/15)

FIG. 13A



SDSA 56 Fluocinolone Release at 37C (0.1% Triton X-100)
% Fluocinolone Released (n=5)
100
80
60
40
20
0
0
28
56
84
112
140
168
196
224
Time (Days)
ENV-1R-0119-49-2 R203S/RG653H (30/70)
ENV-1R-0119-49-1 R203S/RG653H (70/30)
ENV-1R-0119-49-3 R203S/RG653H (85/15)
ENV-1R-0119-49-4 R203S/RG653H (95/5)
ENV-1R-0119-49-7 R203S/RG503H (70/30)
ENV-1R-0119-49-8 R203S/RG503H (85/15)
ENV-1R-0119-49-9 R203S/RG503H (95/5)

FIG. 13B

SDSA 56 Fluocinolone Release at 37C (0.1% Triton X-100)




FIG. 14A



SDSA 59 Fluocinolone Release at 37C (0.1% Triton X-100)
% Fluocinolone Released (n=5)
120
100
80
60
40
20
0
0
28
56
84
112
140
168
196
Time (Days)
ENV-1R-0119-51-2
ENV-1R-0119-51-3
ENV-1R-0119-51-4
ENV-1R-0119-51-7
ENV-1R-0119-51-8
ENV-1R-0119-51-9
ENV-1R-0119-51-16

FIG. 14B



SDSA 59 Fluocinolone Release at 37C (0.1% Triton X-100)
% Fluocinolone Released (n=5)
120
100
80
60
40
20
0
0
28
56
84
112
140
168
196
Time (Days)
ENV-1R-0119-51-5
ENV-1R-0119-51-6
ENV-1R-0119-51-10
ENV-1R-0119-51-11
ENV-1R-0119-51-12
ENV-1R-0119-51-13
ENV-1R-0119-51-21

FIG. 14C



SDSA 59 Fluocinolone Release at 37C (0.1% Triton X-100)
% Fluocinolone Released (n=5)
150
100
50
0
0
28
56
84
112
140
168
196
Time (Days)
ENV-1R-0119-51-14
ENV-1R-0119-51-15

FIG. 15



SDSA 51/52 Release at 37C at sink conditions
Dotted lines: 0.1% Triton X-100
Solid lines: PBS
% Dexamethasone Released (n=2)
0
20
40
60
80
100
120
140
0 14 28 42 56 70 84 98 112 126 140 154 168 182 196 210
Time (Days)
ENV-1R-0159-82-A: RG504S + 20% dex 25x25x50um
ENV-1R-0159-82-B: R203S + 20% dex 25x25x50um
ENV-1R-0159-82-C: R203S/RG504S combo, 20% dex 25x25x50um

FIG. 16



SDSA 47/48 Release at 37C at sink conditions
Dotted lines: 0.1% Triton X-100
Solid lines: PBS
% Dexamethasone Released (n=2)
120
100
80
60
40
20
0
0
14
28
42
56
70
84
98
Time (Days)
ENV-1R-0159-87-A: RG503S + 20% dex 12x12.5x25um
ENV-1R-0159-87-B: RG503S + 20% dex 25x25x25um
ENV-1R-0159-87-C: RG503S + 20% dex 25x25x50um
ENV-1R-0159-87-D: RG503S + 20% dex 50x50x50um

FIG. 17



SDSA 43 Release at 37C at sink conditions (PBS)
% Dexamethasone Released (n=2)
100
80
60
40
20
0
0
28
56
84
112
140
168
196
224
Time (Days)
ENV-1R-0159-57-A, R203/ RG504S (75/25)
ENV-1R-0159-57-B, R203/ RG504S (50/50)
ENV-1R-0159-57-C, R203/ RG504S (25/75)
ENV-1R-0159-57-D, R203S/ RG503H (75/25)
ENV-1R-0159-57-E, R203S/ RG503H (50/50)
ENV-1R-0159-57-F, R203S/ RG503H (25/75)
ENV-1R-0159-57-G, RG504S/ R203S/ RG503S (60/20/20)
ENV-1R-0159-57-H, RG504S/ R203S/ RG503S (33/33/33)
ENV-1R-0159-57-I, RG504S/ R203S/ RG503H (60/20/20)
ENV-1R-159-57-J, 504S/203S/503H (33/33/33)

FIG. 18



SDSA 38 Release at 37C at sink conditions (1X PBS)
% Dexamethasone Released (n=2)
100
80
60
40
20
0
0 14 28 42 56 70 84 98 112 126 140 154
Time (Days)
ENV-1R-159-44-A, DXM/ 203S 20/80, 50x50x50
ENV-1R-159-44-B, DXM/ RG503S 20/80, 50x50x50
ENV-1R-159-44-C, DXM/ RG503H 20/80, 50x50x50
ENV-1R-159-44-D, DXM/ RG504S 20/80, 50x50x50
ENV-1R-159-44-E, DXM/ RG858 20/80, 50x50x50

FIG. 19




FIG. 20




FIG. 21




FIG. 22



Dexamethasone Concentration in
Albino Rabbit Ocular Matrixes
Single Bilateral Administration of 700 µg Dexamethasone on Day 1
Mean +/- SD
n = 4 eyes; Group 1
Dexamethasone Concentration (ng/g or ng/mL)
100000
10000
1000
100
10
1
0.1
0.01
0
28
56
84
Study Day
Retina/Choroid
Vitreous Humor
Aqueous Humor
Ki
LLOQ

FIG. 23



Dexamethasone Concentration in
Albino Rabbit Ocular Matrixes
Single Bilateral Administration of 700 µg Dexamethasone on Day 1
Mean +/- SD
n = 2-4 eyes; Group 2
Dexamethasone Concentration (ng/g or ng/mL)
100000
10000
1000
100
10
1
0.1
0.01
0
28
56
84
Study Day
Retina/Choroid
Vitreous Humor
Aqueous Humor
Ki
LLOQ

FIG. 24



Dexamethasone Concentration in
Albino Rabbit Ocular Matrixes
Single Bilateral Administration of 700 µg Dexamethasone on Day 1
Mean +/- SD
n = 4 eyes; Group 3
Dexamethasone Concentration (ng/g or ng/mL)
100000
10000
1000
100
10
1
0.1
0.01
0
28
56
84
Study Day
Retina/Choroid
Vitreous Humor
Aqueous Humor
Ki
LLOQ

FIG. 25



Dexamethasone Concentration in
Albino Rabbit Ocular Matrixes
Single Bilateral Administration of 270 µg Dexamethasone on Day 1
Mean +/- SD
n = 4 eyes; Group 4
Dexamethasone Concentration (ng/g or ng/mL)
100000
10000
1000
100
10
1
0.1
0.01
0
28
56
84
Study Day
Retina/Choroid
Vitreous Humor
Aqueous Humor
Ki
LLOQ

FIG. 26



A)
Week 1
Mean, ±SD (n=4 eyes/group)
B)
Month 1
Mean, ±SD (n=3-4 eyes/group)
C)
Month 3
Mean, ±SD (n=0-4 eyes/group)
D)
Month 5
Mean, ±SD (n=4 eyes/group)
Dexamethasone Concentration (ng/g or ng/mL)
Group
LLOQ/Ki
Aqueous Humor
Choroid-Punch
Retina-Punch
Vitreous Humor - No Implants
Vitreous Humor - With Implants
Retina/Choroid Non-punch
Plasma

FIG. 27



Dexamethasone Concentration in Albino Rabbit
Vitreous Humor - No Implants
Mean, ±SD (n=3-4 eyes/group)
Dexamethasone Concentration (ng/mL)
1000000
100000
10000
1000
100
10
1
0.1
0
28
56
84
112
140
Day
LLOQ/Ki
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

FIG. 28



Dexamethasone Concentration in Albino Rabbit
Vitreous Humor - With Implants
Mean, ±SD (n=4 eyes/group)
Dexamethasone Concentration (ng/mL)
1000000
100000
10000
1000
100
10
1
0.1
0
28
56
84
112
140
Day
LLOQ/Ki
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

FIG. 29



Dexamethasone Concentration in Albino Rabbit
Retina-Punch
Mean, ±SD (n=3-4 eyes/group)
Dexamethasone Concentration (ng/g)
100000
10000
1000
100
10
1
0.1
0
28
56
84
112
140
Day
LLOQ/Ki
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

FIG. 30



Dexamethasone Concentration in Albino Rabbit Choroid-Punch
Mean, ±SD (n=3-4 eyes/group)
Dexamethasone Concentration (ng/g)
100000
10000
1000
100
10
1
0.1
0
28
56
84
112
140
Day
LLOQ/Ki
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

FIG. 31



Dexamethasone Concentration in Albino Rabbit
Retina/Choroid Non-punch
Mean (n=3-4 eyes/group)
Dexamethasone Concentration (ng/g)
100000
10000
1000
100
10
1
0.1
LLOQ/Ki
0
28
56
84
112
140
Day
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

FIG. 32



Dexamethasone Concentration in Albino Rabbit Aqueous Humor
Mean, ±SD (n=4 eyes/group)
Dexamethasone Concentration (ng/mL)
100
10
1
0.1
0
28
56
84
112
140
Day
LLOQ/Ki
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

FIG. 33




Dexamethasone Concentration in Albino Rabbit Plasma
Mean, ±SD (n=2-6)
Dexamethasone Concentration (ng/mL)
10
1
0.1
LLOQ/Ki
0
28
56
84
112
140
Day
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

FIG. 34


Dexamethasone Concentration in
Albino Rabbit Ocular Matrices
Single Bilateral Administration of 270µg Dexamethasone on Day 1
Mean ±SD; n=4 eyes; Group 4
Dexamethasone Concentration (ng/g)
100000
10000
1000
100
10
1
0.1
0.01
0
28
56
84
Study Day
PRINT - Retina/Choroid
PRINT - Vitreous Humor
Ozurdex* - Vitreous Humor
K_i
LLOQ